TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22978687

Group type: EXPERIMENTAL
Intervention: TSH >30 μU/mL after 4 weeks of thyroid hormone withdrawal (THW)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: TSH >80-100 μU/mL after 4 weeks of THW
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: FACIT-F questionnaire
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: TSH >20 μU/mL with Tg <0.2 ng/mL
Number of subjects: 47
Study: 21300969

Group type: EXPERIMENTAL
Intervention: Accumulated leisure-time sun exposure (age 6 years to current)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Higher actinic skin damage (highest grade vs the lowest)
Number of subjects: 216
Study: 19758258

Group type: EXPERIMENTAL
Intervention: 17% ethylenediaminetetracetic acid (EDTA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite (NaOCl)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride (NaCl)
Number of subjects: 66
Study: 16816226

Group type: EXPERIMENTAL
Intervention: Family focused grief therapy (53 families, 233 individuals)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control condition (28 families, 130 individuals)
Number of subjects: 81
Study: 12508190

Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT)
Number of subjects: 18
Study: 11434951

Group type: EXPERIMENTAL
Intervention: Surgical intervention in KNOOP-3 trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical intervention in TARGET trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-randomised eligible patients
Number of subjects: 0
Study: 9219391

Group type: EXPERIMENTAL
Intervention: Fluoxetine as an adjunct to treatment for cocaine abuse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7962503

Group type: EXPERIMENTAL
Intervention: Osteotomized fibula
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intact fibula
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 3591689

Group type: COMPARATOR
Intervention: Dobutamine therapy at incremental doses of 2.5, 5, 7.5, 10, 12.5 and 15 micrograms/kg/min
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Milrinone as a bolus of 50 or 75 micrograms/kg followed by an infusion of 0.5 to 1.0 micrograms/kg/min
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both milrinone and dobutamine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 79

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 79
Study: 29161767

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 45
Study: 27142057

Group type: EXPERIMENTAL
Intervention: PREPARE intervention (multi-component, school-based HIV prevention intervention)
Number of subjects: 6244

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6244
Study: 25767373

Group type: EXPERIMENTAL
Intervention: Revexepride 1 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Revexepride 1 mg + Omeprazole 40 mg
Number of subjects: 42
Study: 23620327

Group type: EXPERIMENTAL
Intervention: Automatic fetal biometry
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manual fetal biometry
Number of subjects: 200
Study: 21741031

Group type: EXPERIMENTAL
Intervention: Cue-induced reactivity in relapsers
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cue-induced cortisol response
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 19917849

Group type: EXPERIMENTAL
Intervention: Home care program by a nurse
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 164
Study: 16491473

Group type: EXPERIMENTAL
Intervention: Elective anterior resection of the rectum
Number of subjects: 6833

Group type: EXPERIMENTAL
Intervention: Clinical anastomotic leakage
Number of subjects: 6833

Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 6833

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 6833

Group type: EXPERIMENTAL
Intervention: Dukes' 'D' stage
Number of subjects: 6833

Group type: EXPERIMENTAL
Intervention: Intraoperative adverse events
Number of subjects: 6833
Study: 14695468

Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 11059568

Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control
Number of subjects: 67
Study: 9282236

Group type: EXPERIMENTAL
Intervention: Turbuhaler (TH) with 0.5 mg terbutaline
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: pressurized metered-dose inhaler (pMDI) with 0.5 mg terbutaline
Number of subjects: 118

Group type: COMPARATOR
Intervention: Turbuhaler (TH)
Number of subjects: 118

Group type: COMPARATOR
Intervention: pressurized metered-dose inhaler (pMDI)
Number of subjects: 118
Study: 8334346

Group type: EXPERIMENTAL
Intervention: Sheng Mai injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 30
Study: 3113147

Group type: EXPERIMENTAL
Intervention: Naloxone administration (8 mg iv as a bolus followed by an infusion of 4 mg/h for 4 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (200 mg im every two weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 10
Study: 31736457

Group type: EXPERIMENTAL
Intervention: Suicide attempt
Number of subjects: 1326
Study: 29921624

Group type: EXPERIMENTAL
Intervention: Penn Resilience Program for type 1 diabetes (PRP T1D)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Advanced Diabetes Education
Number of subjects: 264
Study: 26526702

Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 14180

Group type: COMPARATOR
Intervention: No arterial hypertension
Number of subjects: 14180
Study: 25551811

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia with 0.5ml (2.5µg) sufentanil added to 1ml hyperbaric bupivacaine (Group BS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Unilateral spinal anaesthesia with 1ml 0.5% hyperbaric bupivacaine (Group B)
Number of subjects: 62
Study: 22032285

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (2 L/min through nasal prongs)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Either oxygen or ASV
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: ASV
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oxygen therapy and ASV
Number of subjects: 10
Study: 21170109

Group type: EXPERIMENTAL
Intervention: S-Gel 5.0 g
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: S-Gel 7.5 g
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 17971716

Group type: EXPERIMENTAL
Intervention: CD4 cell count-guided episodic antiretroviral therapy
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy
Number of subjects: 1225
Study: 21596364

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) added to stable rosuvastatin 5 mg or 10 mg
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus rosuvastatin 5 mg
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus rosuvastatin 10 mg
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) added to stable rosuvastatin
Number of subjects: 440

Group type: COMPARATOR
Intervention: Rosuvastatin up-titration
Number of subjects: 440
Study: 16275885

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil twice daily for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11865971

Group type: COMPARATOR
Intervention: 0.625 mg Cenestin (Synthetic Conjugated Estrogens, A) tablets, administered once daily for 90 days
Number of subjects: 15
Study: 9658709

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study: 7650466

Group type: EXPERIMENTAL
Intervention: Routine breast screening (mammography)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Women receiving false positive results
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Non-attenders
Number of subjects: 1500
Study: 2505269

Group type: EXPERIMENTAL
Intervention: BCG (150 mg)
Number of subjects: 202

Group type: COMPARATOR
Intervention: ADM (50 mg)
Number of subjects: 202

Group type: COMPARATOR
Intervention: TTPA (50 mg)
Number of subjects: 202
Study: 800384

Group type: EXPERIMENTAL
Intervention: Loxapine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Trifluoperazine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Laboratory tests, urine analysis, cardiovascular and ophthalmological investigations
Number of subjects: 57
Study: 11514481

Group type: EXPERIMENTAL
Intervention: Statin treatment for secondary prevention of coronary heart disease (CHD)
Number of subjects: 3963

Group type: EXPERIMENTAL
Intervention: Statin treatment for primary prevention at CHD risk 30% over 10 years
Number of subjects: 3963

Group type: EXPERIMENTAL
Intervention: Statin treatment for primary prevention at CHD risk 20% over 10 years
Number of subjects: 3963

Group type: EXPERIMENTAL
Intervention: Statin treatment for primary prevention at CHD risk 15% over 10 years
Number of subjects: 3963

Group type: EXPERIMENTAL
Intervention: Statin treatment for primary prevention at CHD risk 6% over 10 years
Number of subjects: 3963

Group type: EXPERIMENTAL
Intervention: Statin treatment at projected CHD risk 20% over 10 years
Number of subjects: 3963
Study: 30873671

Group type: EXPERIMENTAL
Intervention: Black seed capsules (500 mg) two times per day for 10 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo two times per day for 10 weeks
Number of subjects: 60
Study: 28539071

Group type: EXPERIMENTAL
Intervention: FlashWord intervention (n = 9)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Delayed Intervention (n = 6)
Number of subjects: 15
Study: 27378000

Group type: EXPERIMENTAL
Intervention: Preoperative dexketoprofen trometamol (25 mg 30 min before surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postoperative dexketoprofen trometamol (25 mg immediately after surgery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preoperative dexketoprofen trometamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postoperative dexketoprofen trometamol
Number of subjects: 60
Study: 24813652

Group type: EXPERIMENTAL
Intervention: Brief intervention (brief advice and input from an AHW)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 802

Group type: COMPARATOR
Intervention: Control (leaflet providing general information on health and lifestyle)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Control
Number of subjects: 802
Study: 22122062

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no KMC)
Number of subjects: 50
Study: 20199786

Group type: COMPARATOR
Intervention: Ezetimibe (10 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Simvastatin (20 mg/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Simvastatin combined with Ezetimibe
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined therapy (Simvastatin + Ezetimibe)
Number of subjects: 50
Study: 17609306

Group type: EXPERIMENTAL
Intervention: 1850 MBq (131)I after rhTSH
Number of subjects: 72

Group type: COMPARATOR
Intervention: 3700 MBq (131)I after rhTSH
Number of subjects: 72
Study: 15889952

Group type: EXPERIMENTAL
Intervention: Oral quetiapine (493 mg/day at week 48)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intramuscular haloperidol decanoate (170 mg/28 days at week 48)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral quetiapine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intramuscular haloperidol decanoate
Number of subjects: 35
Study: 12562481

Group type: EXPERIMENTAL
Intervention: Lateral vertical infraclavicular brachial plexus (LVIBP) block
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lateral vertical infraclavicular brachus plexus (LVIBP) block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Axillary brachial plexus (ABP) block
Number of subjects: 40
Study: 10496715

Group type: EXPERIMENTAL
Intervention: Levovist-enhanced ultrasound
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unenhanced ultrasound
Number of subjects: 18
Study: 8671571

Group type: EXPERIMENTAL
Intervention: High titre measles vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium titre measles vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High titre measles vaccine (females)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High titre measles vaccine (males)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard titre measles vaccine
Number of subjects: 0
Study: 1931060

Group type: EXPERIMENTAL
Intervention: Midazolam 0.02 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thiopental sodium (1.0 mg/kg to 4 mg/kg)
Number of subjects: 50
Study: 6210665

Group type: EXPERIMENTAL
Intervention: mezlocillin (1.5 g) administered intramuscularly every 6 hr for seven to ten days
Number of subjects: 60

Group type: COMPARATOR
Intervention: ticarcillin (2 g) administered intramuscularly every 6 hr for seven to ten days
Number of subjects: 60
Study: 30474314

Group type: EXPERIMENTAL
Intervention: Clear corneal incision with a 2.20 mm keratome
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clear corneal incision with a 2.85 mm keratome
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative corneal first applanation stiffness parameter
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative first applanation velocity
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative second applanation velocity
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative first applanation deformation amplitude
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative deflection amplitude at highest concavity
Number of subjects: 100
Study: 30672213

Group type: EXPERIMENTAL
Intervention: Warm acupuncture at Zusanli (ST 36) and Guanyuan (CV 4) combined with ginger moxibustion at Baliao points, 30 min a time, once a day, 5 times a week for 3 courses (1 month each).
Number of subjects: 50

Group type: COMPARATOR
Intervention: Climen tablet prescribed orally from the 5th day of menstruation, one tablet a time, once a day for 3 months (7 days between two 21-day medication).
Number of subjects: 50
Study: 27107779

Group type: EXPERIMENTAL
Intervention: 20 sessions of accelerated intermittent Theta-burst Stimulation (iTBS) applied to the left dorsolateral prefrontal cortex (DLPFC) over four days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham-controlled iTBS protocol
Number of subjects: 50
Study: 24604606

Group type: EXPERIMENTAL
Intervention: Aspheric IOL (Rayner 920H)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spherical IOL (Rayner 620H)
Number of subjects: 30
Study: 22305715

Group type: EXPERIMENTAL
Intervention: Biomimetic mineralization system (BIMIN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gluma(®) Desensitizer
Number of subjects: 40
Study: 20667889

Group type: EXPERIMENTAL
Intervention: posaconazole 400 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: fosamprenavir/ritonavir 700/100 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: posaconazole 400 mg twice daily with fosamprenavir 700 mg twice daily
Number of subjects: 24
Study: 17125876

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b and ribavirin for 24 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b and ribavirin
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: SVR patients
Number of subjects: 129
Study: 16376207

Group type: EXPERIMENTAL
Intervention: Nonelastic compression garment (CircAid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Four-layer elastic bandage
Number of subjects: 12
Study: 11973215

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625% plus fentanyl 2 microg/mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% plus fentanyl 2 microg/mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 9454395

Group type: EXPERIMENTAL
Intervention: One injection of penicillin
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Penicillin tablets for six days
Number of subjects: 599

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 599

Group type: COMPARATOR
Intervention: Comparison between group A and C
Number of subjects: 599

Group type: COMPARATOR
Intervention: Comparison between group B and C
Number of subjects: 599
Study: 8585875

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy at a dose of 20 mg/die
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: Dietetic treatment and placebo after pravastatin suspension
Number of subjects: 23
Study: 2613719

Group type: EXPERIMENTAL
Intervention: Standardized mechanical conditioning followed by non‐destructive repeated testing to 0.6% strain and a final destructive test
Number of subjects: 121

Group type: COMPARATOR
Intervention: Destructive axial compression test‐series
Number of subjects: 121
Study: 356764

Group type: EXPERIMENTAL
Intervention: Naproxen suppositories
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31832851

Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baseline NK cell proportions
Number of subjects: 60
Study: 31104477

Group type: EXPERIMENTAL
Intervention: E-Leprosy framework with SMS reminders
Number of subjects: 188
Study: 27640940

Group type: EXPERIMENTAL
Intervention: Tension on transcervical balloon catheter
Number of subjects: 140

Group type: COMPARATOR
Intervention: No tension on transcervical balloon catheter
Number of subjects: 140
Study: 25035081

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23313720

Group type: EXPERIMENTAL
Intervention: Intervention program (n = 54)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Attention and dose‐matched control program (n = 52)
Number of subjects: 106
Study: 22428515

Group type: EXPERIMENTAL
Intervention: 25 microg of fentanyl added to 2.5 mls of 0.5% hyperbaric bupivacaine intrathecally
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2.5 mls of 0.5% hyperbaric bupivacaine intrathecally
Number of subjects: 60
Study: 19620953

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study: 17445897

Group type: EXPERIMENTAL
Intervention: AcrySof IQ
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AcrySof SN60AT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sensar AR40
Number of subjects: 120
Study: 15372170

Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 35
Study: 11354524

Group type: EXPERIMENTAL
Intervention: Type A Behavior Pattern (TABP) classification using Structured Interview (SI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Incremental cycling test
Number of subjects: 44
Study: 10668412

Group type: EXPERIMENTAL
Intervention: CP-101,606 (0.75 mg/kg/hr for 2 hours, then 0.37 mg/kg/hr for 22 or 70 hours)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 7787152

Group type: EXPERIMENTAL
Intervention: Ultra Twin bag system
Number of subjects: 82

Group type: COMPARATOR
Intervention: Ultra Y-set system
Number of subjects: 82
Study: 2110537

Group type: EXPERIMENTAL
Intervention: Morniflumate suppositories (400 mg, twice daily for 4 days)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (twice daily for 4 days)
Number of subjects: 101
Study: 6772048

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Neurolept anaesthesia
Number of subjects: 46
Study: 31115111

Group type: EXPERIMENTAL
Intervention: Prophylactic factor VIII (FVIII) concentrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Episodic treatment for bleeding
Number of subjects: 0
Study: 27893480

Group type: EXPERIMENTAL
Intervention: High-speed resistance training
Number of subjects: 14
Study: 25239479

Group type: EXPERIMENTAL
Intervention: CKD‐EPI equation
Number of subjects: 6083

Group type: COMPARATOR
Intervention: MDRD equation
Number of subjects: 6083
Study: 23604336

Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21955465

Group type: EXPERIMENTAL
Intervention: Enhanced Internet intervention with a large online social network
Number of subjects: 1326
Study: 19996674

Group type: EXPERIMENTAL
Intervention: Test group implants placed 2 mm supracrestally
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group implants positioned at bone level
Number of subjects: 26
Study: 17196489

Group type: EXPERIMENTAL
Intervention: Medial branch blocks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pericapsular blocks
Number of subjects: 26
Study: 15145175

Group type: EXPERIMENTAL
Intervention: Proton-photon radiotherapy, mean prescribed dose 76.3 CGE
Number of subjects: 85
Study: 11773293

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy for 1-3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy for 5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy for longer than 5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing tamoxifen duration trials (aTTom and ATLAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crossover to other hormonal interventions after 5 years of tamoxifen
Number of subjects: 0
Study: 11385383

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 70

Group type: COMPARATOR
Intervention: Elderly patients undergoing urologic surgery
Number of subjects: 70
Study: 9363342

Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph (HRT) optic disc shape measures
Number of subjects: 226